Grupo para la caracterización molecular de las neoplasias hematológicas

Foto de Grupo para la caracterización molecular de las neoplasias hematológicas

Foto de University of New Brunswick

University of New Brunswick

Saint John, Canadá

Publicaciones en colaboración con investigadores/as de University of New Brunswick (5)

2023

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
American Journal of Hematology

2022

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
HemaSphere, Vol. 6, Núm. 12, pp. E801
MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S411-S412

2020

Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia
Journal of Clinical Oncology

2014

New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542